论文部分内容阅读
采用多聚酶链式反应-序列特异引物(pcr-ssp)方法检测65例GD病人抗甲状腺药物引起粒细胞减少(1)组,65例GD病人并发粒细胞减少(2)组,65例非GD病人粒细胞减少(3)组,65例正常参照人群(4)组的HLA-DRB1*08032 DRB1*1501的等位基因频率。结果1:(1)组HLA-DRB1*08032 DRB1*1501的基因频率高于(2)组(P<0.05)。2:(1)组HLA-DRB1*08032 DRB1*1501的基因频率明显高于(3)组(4)组,(P<0.01)。3:(2)组HLA-DRB1*08032DRB1*1501的基因频率高于(4)组(P<0.05)。结论:GD病人应用抗甲状腺药物引起粒细胞减少与HLA-DRB1*08032DRB1*1501等位基因频率增加有关。
Sixty-five patients with GD were tested for antithyroid-induced neutropenia by polymerase chain reaction-sequence-specific primer (pcr-ssp) method (group 1), 65 patients with GD with neutropenia (Group 2) and 65 patients with non-GD The allele frequency of HLA-DRB1 * 08032 DRB1 * 1501 in the group of neutropenia (3) and 65 normal controls (4). Results 1: The frequency of HLA-DRB1 * 08032 DRB1 * 1501 gene in group 1 was higher than that in group 2 (P <0.05). 2: (1) The gene frequencies of HLA-DRB1 * 08032 DRB1 * 1501 in group 1 were significantly higher than those in group 3 and group 4 (P <0.01). 3: (2) The gene frequency of HLA-DRB1 * 08032DRB1 * 1501 group was higher than that of (4) group (P <0.05). Conclusion: The anti-thyroid drug-induced neutropenia in patients with GD is associated with an increased frequency of HLA-DRB1 * 08032DRB1 * 1501 alleles.